Results 211 to 220 of about 13,786,958 (257)

Correction: Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study. [PDF]

Blood Cancer J
Narula G, Keerthivasagam S, Jain H, Punatar S, Chichra A, Dhamne C, Tembhare P, Subramanian PG, Patkar N, Poojary M, Gokarn A, Mirgh S, Jindal N, Nisar A, Pandit D, Pandit K, Dwivedi A, Karulkar A, Jaiswal AK, Khan A, Shah S, Rafiq A, Basu M, Pendhari J, Asija S, Chowdury A, Banik A, Moulik NR, Srinivasan S, Bhosle S, Hiregoudar S, Ojha S, Nayak L, Thorat J, Bagal B, Sengar M, Khattry N, Banavali S, Highfill S, Shah NN, Purwar R.   +40 more
europepmc   +1 more source

Outcomes of adult patients with Li‐Fraumeni syndrome and myeloid neoplasms

Cancer, Volume 132, Issue 19, 1 October 2026.
Abstract Background Li‐Fraumeni syndrome (LFS) is an inherited cancer predisposition syndrome. Hematologic malignancies are not considered LFS defining tumors, however, both acute lymphoblastic leukemia and therapy‐related myeloid neoplasms (MNs) in LFS are described. Treatment approaches and outcomes of MN in LFS need further evaluation.
Jayastu Senapati, Hiam M. Abdel‐Salam, Vladislav D. Jdanov, Sanam Loghavi, Ashley Woodson, Jessica Corredor, Gautam Borthakur, Naval G. Daver, Tapan M. Kadia, Koichi Takahashi, Yesid Alvarado, Naveen Pemmaraju, Uday R. Popat, Elizabeth J. Shpall, Farhad Ravandi, Florencia McAllister, Najat C. Daw, Guillermo Garcia‐Manero, Banu K. Arun, Courtney D. DiNardo   +19 more
wiley   +1 more source

siRNA-mediated inhibition of hTERT enhances the effects of curcumin in promoting cell death in precursor-B acute lymphoblastic leukemia cells: an in silico and in vitro study. [PDF]

Sci Rep
Ashoub MH, Afgar A, Farsinejad A, Razavi R, Anvari S, Fatemi A.   +5 more
europepmc   +1 more source

Model‐Based Analysis with Mechanistic Insights to CAR‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1027-1040, October 2026.
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin, Martin Bergstrand, Ana Ruiz‐Garcia, Simone Filosto, Rhine Shen   +4 more
wiley   +1 more source

Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study. [PDF]

Blood Cancer J
Narula G, Keerthivasagam S, Jain H, Punatar S, Chichra A, Dhamne C, Tembhare P, Subramanian PG, Patkar N, Poojary M, Gokarn A, Mirgh S, Jindal N, Nisar A, Pandit D, Pandit K, Dwivedi A, Karulkar A, Jaiswal AK, Khan A, Shah S, Rafiq A, Basu M, Pendhari J, Asija S, Chowdury A, Banik A, Moulik NR, Srinivasan S, Bhosle S, Hiregoudar S, Ojha S, Nayak L, Thorat J, Bagal B, Sengar M, Khattry N, Banavali S, Highfill S, Shah NN, Purwar R.   +40 more
europepmc   +1 more source

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS).
Clare J. Rowntree, Amy A. Kirkwood, Nadine Farah, Emma Lawrie, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Bela Patel, Pip Patrick, Paul Smith, Krisztina Z. Alapi, Lingyi Wang, Marc R. Mansour, Adele K. Fielding   +14 more
wiley   +1 more source

A pre-B acute lymphoblastic leukemia cell line model reveals the mechanism of thalidomide therapy-related B-cell leukemogenesis. [PDF]

J Biol Chem
Ramani M, Singh RK, Shrivastva S, Ribeyron L, Gupta SK, Roy A.   +5 more
europepmc   +1 more source

The 9th Edition of the UICC TNM Classification of Malignant Tumours: Updates and Rationale for Change

International Journal of Cancer, Volume 159, Issue 7, Page 1588-1601, 1 October 2026.
ABSTRACT The standard for assessing and recording the extent of the tumour, a necessity for most malignancies, is the Tumour Node Metastases (TNM) classification. The Union for International Cancer Control (UICC) TNM committee has defined this since the early 1950s.
James D. Brierley, Liesbet J. Van Eycken, Meredith E. Giuliani, Brian A. Rous, Shao Hui Huang, Hisao Asamura, Mary K. Gospodarowicz, Anne W. Lee, Brian O'Sullivan   +8 more
wiley   +1 more source

IKZF1^plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia. [PDF]

Front Oncol
Garcia-Solorio J, Núñez-Enriquez JC, Jiménez-Olivares M, Flores-Lujano J, Flores-Espino F, Molina-Garay C, Cervera A, Casique-Aguirre D, Peñaloza-Gonzalez JG, Baños-Lara MDR, García-Soto Á, Galván-Díaz CA, Olaya-Vargas A, Aguilar HF, Mata-Rocha M, Garrido-Hernández MÁ, Solís-Poblano JC, Luna-Silva NC, Cano-Cuapio LS, Aristil-Chery PM, Herrera-Quezada F, Carrillo-Sanchez K, Muñoz-Rivas A, Flores-Lagunes LL, Mendoza-Caamal EC, Villegas-Torres BE, González-Osnaya V, Jiménez-Hernández E, Torres-Nava JR, Martín-Trejo JA, Gutiérrez-Rivera ML, Espinosa-Elizondo RM, Merino-Pasaye LE, Pérez-Saldívar ML, Jiménez-Morales S, Curiel-Quesada E, Rosas-Vargas H, Mejía-Arangure JM, Alaez-Verson C.   +38 more
europepmc   +1 more source

A Germline ETV6 Missense Variant in a Family With Thrombocytopenia and Leukemia Predisposition: A Case Report

eJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Germline pathogenic variants in ETV6 are recognized as causes of inherited thrombocytopenia and leukemia predisposition. We report a family harboring a germline ETV6 variant, c.1072A>T (p.I358F), which has not been previously associated with this phenotype. Three family members exhibited chronic thrombocytopenia, and two had a history of acute
Tomoko Waragai, Yoshiko Nakano, Kazuhiro Mochizuki, Atsushi Kikuta, Mitsuko Akaihata, Nobuhisa Takahashi, Shingo Kudo, Yui Sasaki, Motohiro Kato, Hideki Sano   +9 more
wiley   +1 more source